GlassScriptPhysician profile
Kelli N Anzalone
NPI 1689911943
$816.26
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $530 · 2022: $287.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $411.86 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.47 | 2021-2022 | |
| Abbvie INC. | $65.04 | 2021-2022 | |
| Lilly USA, LLC | $58.15 | 2021 | |
| Abbott Laboratories | $52.19 | 2021-2022 | |
| Dexcom, INC. | $45.93 | 2021-2022 | |
| Amarin Pharma, INC. | $23.57 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $17.03 | 2021 | |
| Cranial Technologies, INC | $16.70 | 2021 | |
| Janssen Pharmaceuticals, INC | $15.52 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.80 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelli Anzalone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.